SAMEA2690202	Blood Normal/Reference sample	Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690202	Blood Normal/Reference sample	Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690202	Blood Normal/Reference sample	Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690202	Blood Normal/Reference sample	Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA4012189	CPCGene Prostate Cancer Samples	donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;Gleason Score=4+5;IDC-P Status=Positive (20-40%);phenotype=Prostate Cancer;Sample=CPCG0100-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012190	CPCGene Prostate Cancer Samples	donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG0100-F3;Tissue Source=UHN-Toronto,Canada;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
SAMEA4012191	CPCGene Prostate Cancer Samples	donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative (LCM);phenotype=Prostate Cancer;Sample=CPCG0100-F5;Tissue Source=UHN-Toronto,Canada;Tissue Type=Invasive Ca;ENA-CHECKLIST=ERC000026;
SAMEA4012192	CPCGene Prostate Cancer Samples	donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0100-F6;Tissue Source=UHN-Toronto,Canada;Tissue Type=Benign Epithelium;ENA-CHECKLIST=ERC000026;
SAMEA4012193	CPCGene Prostate Cancer Samples	donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
SAMEA4012193	CPCGene Prostate Cancer Samples	donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
SAMEA4012193	CPCGene Prostate Cancer Samples	donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
SAMEA4012194	CPCGene Prostate Cancer Samples	donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;Gleason Score=3+4;IDC-P Status=Positive (15%);phenotype=Prostate Cancer;Sample=CPCG0103-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012195	CPCGene Prostate Cancer Samples	donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG0103-F2;Tissue Source=UHN-Toronto,Canada;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
SAMEA4012196	CPCGene Prostate Cancer Samples	donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0103-F4;Tissue Source=UHN-Toronto,Canada;Tissue Type=Benign Epithelium;ENA-CHECKLIST=ERC000026;
SAMEA2690234	Blood Normal/Reference sample	Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690234	Blood Normal/Reference sample	Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690234	Blood Normal/Reference sample	Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690235	Prostate Tumour sample	Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012197	CPCGene Prostate Cancer Samples	donor_id=CPCG0196;gender=male;Germline BRCA Status=WT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG0196-F2;Tissue Source=UHN-Toronto,Canada;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
SAMEA4012198	CPCGene Prostate Cancer Samples	donor_id=CPCG0196;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative (LCM);phenotype=Prostate Cancer;Sample=CPCG0196-F3;Tissue Source=UHN-Toronto,Canada;Tissue Type=Invasive Ca;ENA-CHECKLIST=ERC000026;
SAMEA2690287	Blood Normal/Reference sample	Age at Treatment=65.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.59;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690287	Blood Normal/Reference sample	Age at Treatment=65.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.59;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690287	Blood Normal/Reference sample	Age at Treatment=65.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.59;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690287	Blood Normal/Reference sample	Age at Treatment=65.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.59;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690288	Prostate Tumour sample	Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012199	CPCGene Prostate Cancer Samples	donor_id=CPCG0260;gender=male;Germline BRCA Status=WT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG0260-F2;Tissue Source=UHN-Toronto,Canada;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
SAMEA4012200	CPCGene Prostate Cancer Samples	donor_id=CPCG0260;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative (LCM);phenotype=Prostate Cancer;Sample=CPCG0260-F3;Tissue Source=UHN-Toronto,Canada;Tissue Type=Invasive Ca;ENA-CHECKLIST=ERC000026;
SAMEA4012201	CPCGene Prostate Cancer Samples	donor_id=CPCG0260;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0260-F4;Tissue Source=UHN-Toronto,Canada;Tissue Type=Benign Epithelium;ENA-CHECKLIST=ERC000026;
SAMEA2690307	Blood Normal/Reference sample	Age at Treatment=53.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690307	Blood Normal/Reference sample	Age at Treatment=53.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690307	Blood Normal/Reference sample	Age at Treatment=53.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690308	Prostate Tumour sample	Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012202	CPCGene Prostate Cancer Samples	donor_id=CPCG0334;gender=male;Germline BRCA Status=WT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG0334-F2;Tissue Source=UHN-Toronto,Canada;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
SAMEA4012203	CPCGene Prostate Cancer Samples	donor_id=CPCG0334;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative (LCM);phenotype=Prostate Cancer;Sample=CPCG0334-F3;Tissue Source=UHN-Toronto,Canada;Tissue Type=Invasive Ca;ENA-CHECKLIST=ERC000026;
SAMEA2690345	Blood Normal/Reference sample	Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690345	Blood Normal/Reference sample	Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690345	Blood Normal/Reference sample	Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690345	Blood Normal/Reference sample	Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690346	Prostate Tumour sample	Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012204	CPCGene Prostate Cancer Samples	donor_id=CPCG0361;gender=male;Germline BRCA Status=WT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG0361-F2;Tissue Source=UHN-Toronto,Canada;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
SAMEA4012205	CPCGene Prostate Cancer Samples	donor_id=CPCG0361;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative (LCM);phenotype=Prostate Cancer;Sample=CPCG0361-F3;Tissue Source=UHN-Toronto,Canada;Tissue Type=Invasive Ca;ENA-CHECKLIST=ERC000026;
SAMEA4012206	CPCGene Prostate Cancer Samples	donor_id=CPCG0361;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0361-F4;Tissue Source=UHN-Toronto,Canada;Tissue Type=Benign Epithelium;ENA-CHECKLIST=ERC000026;
SAMEA2690351	Blood Normal/Reference sample	Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690351	Blood Normal/Reference sample	Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690351	Blood Normal/Reference sample	Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690351	Blood Normal/Reference sample	Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
SAMEA2690352	Prostate Tumour sample	Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012207	CPCGene Prostate Cancer Samples	donor_id=CPCG0364;gender=male;Germline BRCA Status=WT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG0364-F2;Tissue Source=UHN-Toronto,Canada;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
SAMEA4012208	CPCGene Prostate Cancer Samples	donor_id=CPCG0364;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative (LCM);phenotype=Prostate Cancer;Sample=CPCG0364-F3;Tissue Source=UHN-Toronto,Canada;Tissue Type=Invasive Ca;ENA-CHECKLIST=ERC000026;
SAMEA4012209	CPCGene Prostate Cancer Samples	donor_id=CPCG0364;gender=male;Germline BRCA Status=WT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0364-F4;Tissue Source=UHN-Toronto,Canada;Tissue Type=Benign Epithelium;ENA-CHECKLIST=ERC000026;
SAMEA4012210	CPCGene Prostate Cancer Samples	donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
SAMEA4012211	CPCGene Prostate Cancer Samples	donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0450-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012212	CPCGene Prostate Cancer Samples	donor_id=CPCG0556;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0556-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
SAMEA4012213	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9001;ENA-CHECKLIST=ERC000026;
SAMEA4012213	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9001;ENA-CHECKLIST=ERC000026;
SAMEA4012214	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9001;ENA-CHECKLIST=ERC000026;
SAMEA4012215	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9001;ENA-CHECKLIST=ERC000026;
SAMEA4012216	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9002;ENA-CHECKLIST=ERC000026;
SAMEA4012216	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9002;ENA-CHECKLIST=ERC000026;
SAMEA4012217	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9002;ENA-CHECKLIST=ERC000026;
SAMEA4012218	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9002;ENA-CHECKLIST=ERC000026;
SAMEA4012219	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9003;ENA-CHECKLIST=ERC000026;
SAMEA4012219	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9003;ENA-CHECKLIST=ERC000026;
SAMEA4012220	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9003;ENA-CHECKLIST=ERC000026;
SAMEA4012221	CPCGene Prostate Cancer Samples	gender=male;phenotype=Prostate Cancer;donor_id=CPCG9003;ENA-CHECKLIST=ERC000026;
SAMEA4012222	CPCGene Prostate Cancer Samples	donor_id=CPCG9004;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative (LCM);phenotype=Prostate Cancer;Sample=CPCG9004-P1;Tissue Source=Australia;Tissue Type=Invasive Ca;ENA-CHECKLIST=ERC000026;
SAMEA4012223	CPCGene Prostate Cancer Samples	donor_id=CPCG9004;gender=male;Germline BRCA Status=MT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG9004-P2;Tissue Source=Australia;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
SAMEA4012224	CPCGene Prostate Cancer Samples	donor_id=CPCG9005;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG9005-B1;Tissue Source=Australia;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
SAMEA4012224	CPCGene Prostate Cancer Samples	donor_id=CPCG9005;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG9005-B1;Tissue Source=Australia;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
SAMEA4012225	CPCGene Prostate Cancer Samples	donor_id=CPCG9005;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative (LCM);phenotype=Prostate Cancer;Sample=CPCG9005-P1;Tissue Source=Australia;Tissue Type=Invasive Ca;ENA-CHECKLIST=ERC000026;
SAMEA4012226	CPCGene Prostate Cancer Samples	donor_id=CPCG9005;gender=male;Germline BRCA Status=MT;IDC-P Status=Positive (LCM);phenotype=Prostate Cancer;Sample=CPCG9005-P2;Tissue Source=Australia;Tissue Type=IDC-P;ENA-CHECKLIST=ERC000026;
